The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Midatech Pharma gets approval for next MTD201 study

Fri, 20th Sep 2019 15:43

(Sharecast News) - Biotechnology company Midatech Pharma has received approval to commence a phase 1 study on MTD201, which it is developing for the treatment of acromegaly and neuroendocrine tumours (NET).

The AIM-traded firm said it was the next stage in its development plan for MTD201, as it outlined in an announcement on 13 June.

It explained that the objective of the study was to investigate subcutaneous administration as an additional injection route, compared to intramuscular administration.

The study, which was being conducted in 28 healthy subjects, could now begin, with data available towards the end of 2019 or early in 2020.

Midatech said the objective was to determine the administration route for the pivotal registration study, which would begin in 2020.

The earlier study conducted in 2018 demonstrated MTD201 to have a favourable long-acting clinical profile, the board explained, with "significantly lower variability" in release kinetics, and no initial burst release of the active ingredient - octreotide - when compared to Novartis' 'Sandostatin' LAR® (SLAR).

Combined with the other advantages of Midatech's 'Q-Sphera' technology, including less painful injections due to smaller needle size, and simpler, more reliable reconstitution and injection, the company said it believed MTD201 was "well positioned" as a next-generation long-acting agent in the $2.5bn somatostatin analogue market.

In addition to the advantages shown in the earlier study, the Q-Sphera technology provided the flexibility for unit doses above 30mg, longer dosing intervals up to six to eight weeks, and subcutaneous administration of octreotide, none of which the firm believed were possible with the manufacturing process used for SLAR.

That would provide the opportunity for further "well-differentiated" octreotide products and an enhanced potential for MTD201 to compete with existing long-acting somatostatin analogues.

The subcutaneous route of administration being evaluated in the new study would further reduce pain on injection, and allow the potential for self-administration at home without the need to for hospital visits to receive drug injections.

Preparation for the next pivotal phase of clinical development for MTD201 in 2020 was also underway, Midatech confirmed.

It said that, following confirmation of the MTD201 administration route from the phase 1 study, the pivotal registration study in acromegaly patients was planned to start early in 2020.

Subject to funding, a pivotal registration programme to support a second indication in NET was also expected to start in 2020.

"We are very pleased to have received approval to start this phase 1 study which we believe will demonstrate the clear advantages of the MTD201 product utilising our Q-Sphera technology," said Midatech Pharma's chief executive officer Dr Craig Cook.

"I look forward to providing regular updates as the development programme progresses."
More News
20 Sep 2019 13:30

Midatech Pharma Secures Approval To Commence MTD201 First-Phase Study

(Alliance News) - Midatech Pharma PLC on Friday said it has received approval to start a first phase of study on MTD201, which it is developing for the treatment of acromegaly and neuroendocrine a

Read more
11 Sep 2019 12:09

Midatech Secures Spanish Government Loan To Fund MTD201 Cancer Drug

(Alliance News) - Midatech Pharma PLC's shares surged on Wednesday as said it has received a EUR6.6 million loan from the Spanish government to finance manufacturing work in its facility in in

Read more
9 Sep 2019 12:20

Midatech Pharma Appoints Former Ergomed CEO As Chief Financial Officer

(Alliance News) - Immunotherapy-focused pharmaceutical company Midatech Pharma PLC said Monday it has appointed Stephen Stamp as chief financial officer with immediate effect.He will be who

Read more
31 Jul 2019 15:54

MidaTech Pharma Appoints Frederic Duchesne As Non-Executive Director

(Alliance News) - Midatech Pharma PLC said Wednesday that Frederic Duchesne had been appointed as a non-executive director, effective immediately.Duchesne was chief executive of the of May.

Read more
19 Jul 2019 12:21

Midatech Pharma Shares Surge After Positive Diabetes Treatment Results

(Alliance News) - Shares in biopharmaceutical firm Midatech Pharma PLC surged Friday after it received positive results from its first-in-human study of its MTX102 diabetes vaccine in Midatech 13%

Read more
3 Jul 2019 12:35

Midatech Adds Two Higher Dose Levels To MTX110 Brain Tumour Drug Study

(Alliance News) - Midatech Pharma PLC on Wednesday said two higher dose levels have been added to its study of brain tumour drug MTX110 as it has been well tolerated.Shares in the oncology

Read more
13 Jun 2019 16:20

Midatech Finalises Development Plan For Acromegaly Treatment MTD201

(Alliance News) - Midatech Pharma PLC on Thursday said it has finalised the development plan for MTD201 as a treatment in patients with acromegaly and neuroendocrine tumours using its Q-Sphera in

Read more
12 Jun 2019 16:04

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 13 JuneTescoWM Morrison SupermarketsSirius MineralsJust Jack 14 Evans 17 18

Read more
24 Apr 2019 11:41

Midatech Pharma mired in losses as R&D costs mount

(Sharecast News) - Midatech Pharma's shares dropped on Wednesday as the company reported an annual loss and falling cash balances, though it remained confident in its ability to create value over the next 18-24 months.

Read more
24 Apr 2019 10:54

Midatech Pharma Loss Narrows As Revenue Rises Amid Refocused Business

LONDON (Alliance News) - Midatech Pharma PLC on Wednesday reported a narrowed annual loss on the back of increased revenue generation and said that the company has entered into a "new of US a

Read more
29 Mar 2019 10:40

WINNERS & LOSERS SUMMARY: TUI Hit By Grounding Of Boeing 737 Max Jet

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - up 2.5%, Glencore, up 2.6%,

Read more
29 Mar 2019 10:27

Midatech Pharma Shares Jump After Spanish Government Approves Loan

LONDON (Alliance News) - Midatech Pharma PLC on Friday said it received approval of a EUR6.6 million loan from the Spanish government for commercial scale-up of the company's cancer treatment

Read more
25 Feb 2019 15:49

Midatech Pharma Raises GBP13.4 Million In Placing And Open Offer (ALLISS)

LONDON (Alliance News) - Midatech Pharma PLC on Monday said it raised GBP13.4 million in a placing, subscription and open offer of shares at 3.85 pence each.Application has been made by the

Read more
4 Feb 2019 18:38

UPDATE: Midatech Raises GBP4.7 Million After Placing And Open Offer (ALLISS)

LONDON (Alliance News) - Midatech Pharma PLC said Monday it has raised GBP4.7 million via a share placing and open offer.Midatech said the placing and open offer was made at 3.85 pence for

Read more
4 Feb 2019 16:01

Midatech Seeks To Raise GBP4.8 Million From Placing And Open Offer (ALLISS)

LONDON (Alliance News) - Midatech Pharma PLC said Monday it intends to raise a minimum of GBP4.0 million from a share placing, plus up to GBPP750,000 from an open offer.Midatech, a research

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.